Reinier Boon

Reinier Boon serves as DZHK Professor for RNA Therapeutics at Goethe University Frankfurt, holding dual affiliations at the Institute for Cardiovascular Regeneration (Frankfurt, Germany) and the Department of Physiology at VU University Medical Center (Amsterdam, Netherlands). His research program, funded by the German Center for Cardiovascular Research (DZHK) and an ERC Starting Grant, focuses on molecular mechanisms of cardiovascular aging.

Prof. Boon's laboratory investigates how non-coding RNAs regulate age-related deterioration in endothelial cells and cardiomyocytes, with particular emphasis on long non-coding RNAs (H19, Meg3, MALAT1) and microRNAs (miR-34a, miR-29). His work has identified critical roles for these molecules in cellular senescence, metabolic regulation, and vascular dysfunction, revealing novel pathways involving Stat3 signaling, KLF2 transcription factors, and extracellular matrix remodeling. This research bridges fundamental molecular biology with therapeutic development for age-related cardiovascular diseases.

Analysis of his key publications (2011-2019) reveals a consistent trajectory from mechanistic discoveries in RNA biology to translational applications, with increasing focus on therapeutic targeting of non-coding RNAs in vascular aging and regenerative processes. The work spans endothelial metabolism, cardiac aging, neovascularization, and aortic pathology, demonstrating strong interdisciplinary integration of molecular cardiology, regenerative medicine, and RNA therapeutics.

Major recognitions include:

• European Society of Cardiology Outstanding Achievement Award (2019)
• ERC Starting Grant (2015)
• Franz-Maximilian Groedel Research Prize (2014)
• Dutch-German Young Investigator Award (2013)
• American Heart Association Melvin L. Marcus Award (2010)

Prof. Boon leads an internationally collaborative research group supported by DZHK infrastructure and competitive grants. His laboratory directs multiple projects on RNA-based interventions for cardiovascular aging, with strong emphasis on translational validation. The group maintains active collaborations across European cardiovascular research networks and participates in DZHK's therapeutic development initiatives.

The Boon Group operates across two specialized sites: the Institute for Cardiovascular Regeneration at Frankfurt's Center for Molecular Medicine and Amsterdam's VU University Medical Center physiology department. As part of the DZHK's RNA Therapeutics program, the team combines advanced molecular techniques with disease models to develop novel strategies against age-related cardiovascular decline.